RxSight receives FDA request for additional info on lower-cost LDD; expects no timeline impact

RxSight, Inc.

FDA requested additional information for approval of lower-cost-to-manufacture Light Delivery Device (LDD).
Commercial sale of the lower-cost LDD not planned until 2023; company believes it can meet the timeline.
Lower-cost LDD has the same functionality as the currently marketed LDD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.